FOR IMMEDIATE RELEASE: 2023/4/10
M3, Inc.
Edanz Inc.

M3 Acquires Scribendi Inc. in Canada~ Strengthen Research Paper Editing Platform and Accelerate its Globalization ~M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL: https://corporate.m3.com/en;“M3” below) has announced the acquisition via its subsidiary Edanz Inc. (“Edanz” below), of ScribendiInc. (Headquarters: Chatham, ON, Canada URL: https://www.scribendi.com andhttps://www.scribendi.ai; “Scribendi,” below), which provides global editing and proofreading services.
M3, Inc.
M3 operates m3.com, a specialized web portal for medical professionals that delivers healthcare
related information to its 320,000+ physician members in Japan. Presence outside of Japan includes
the U.S., U.K., France, China, Korea, and India, with aggressive business expansion overseas thathas amassed over 6 million physicians as members across its global platforms. This allows theprovision of services including marketing support, marketing research, and job placement support thatleverage the platform’s powerful value as a media channel.
Edanz
Edanz owns a freelance platform with approximately 500 top-class scientific and medical researchprofessionals (mainly English native speakers and Ph.D. holders), supporting the drafting and editingof research papers mainly within the medical field. As the pioneer in this field, they are a globallyleading company within English editing services for research papers. Edanz caters to clients in over
120 countries, mainly in academia including The University of Tokyo and Peking University,
pharmaceutical companies, and hospitals. With a repeat rate of over 80%, Edanz is highly regardedin the research community, and has supported the preparation of more than 330,000 manuscripts, aswell as the development of more than 600 clinical research papers for pharmaceutical companies inJapan.
Scribendi
Scribendi owns an editing and proofreading platform with approximately 400 active freelancers
and provides services to 28,000 clients annually, including the global academic community, students,researchers, authors, companies, and individuals for whom English is a second language. Thecompany also operates on a proprietary platform and has developed its own natural language
processing (NLP) AI technologies based on a dataset of more than 30 million sentences annotatedby professional editors to mirror the workings of the human brain. Among other things, theirtechnologies can automatically correct grammar, measure quality, and automate the process fromreceiving an order to delivery, thereby shortening lead time to only 2 hours on its platform.

Expected Synergies
Edanz and Scribendi are geographically and functionally complementary. This acquisition enables
Edanz to further strengthen its capability to provide editing and publication support services to global
clients promptly through Scribendi’s automated End-to-End platform. Edanz will also seek groupsynergies by introducing its medical writing and high-end research support services on Scribendi’s
platform as well as introducing Scribendi to M3’s global platform of doctors, pharmaceutical companies,and CROs.

Scribendi Website

Scribendi Overview
Company: Scribendi Inc.
Established: 1997
Headquarters: Chatham, ON, Canada
URL: https://www.scribendi.com and https://www.scribendi.ai
CEO: Koji Yamashita
Business: operation of an editing and proofreading platform